Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Andrew Conrad, Robert Hoffman

Premium

SynapDx this week appointed Andrew Conrad to the company's board of directors.

Conrad recently joined Google to participate in its Google X investigative laboratory. He previously served as chief scientific officer and executive vice president of Laboratory Corporation of America and is co-founder of its National Genetics Institute.

Conrad's appointment coincided with Google Ventures' recent investment in SynapDx, which is developing expression array-based tests for autism (see related story, this issue).


CombiMatrix has appointed Robert Hoffman to its board of directors.

Hoffman has been senior vice president of finance and chief financial officer at Arena Pharmaceuticals, a San Diego-based biopharma company, since 1997. He is also a member of the business and financial advisory board of Innovus Pharmaceuticals, a La Jolla, Calif.-based pharmaceuticals company.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.